-
1
-
-
0036789184
-
Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability
-
Hermsen M, Postma C, Baak J, Weiss M, Rapallo A, Sciutto A, et al. Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. Gastroenterology 2002;123: 1109-19.
-
(2002)
Gastroenterology
, vol.123
, pp. 1109-1119
-
-
Hermsen, M.1
Postma, C.2
Baak, J.3
Weiss, M.4
Rapallo, A.5
Sciutto, A.6
-
2
-
-
33845608798
-
Classification of colorectal cancer based on correlation of clinical, morphological and molecular features
-
Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50:113-30.
-
(2007)
Histopathology
, vol.50
, pp. 113-130
-
-
Jass, J.R.1
-
3
-
-
0034827025
-
The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas
-
Cunningham JM, Kim CY, Christensen ER, Tester DJ, Parc Y, Burgart LJ, et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 2001;69:780-90.
-
(2001)
Am J Hum Genet
, vol.69
, pp. 780-790
-
-
Cunningham, J.M.1
Kim, C.Y.2
Christensen, E.R.3
Tester, D.J.4
Parc, Y.5
Burgart, L.J.6
-
4
-
-
0032146118
-
Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability
-
Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC, Burgart LJ, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998;58:3455-60.
-
(1998)
Cancer Res
, vol.58
, pp. 3455-3460
-
-
Cunningham, J.M.1
Christensen, E.R.2
Tester, D.J.3
Kim, C.Y.4
Roche, P.C.5
Burgart, L.J.6
-
5
-
-
0031017268
-
Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines
-
Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997;57:808-11.
-
(1997)
Cancer Res
, vol.57
, pp. 808-811
-
-
Kane, M.F.1
Loda, M.2
Gaida, G.M.3
Lipman, J.4
Mishra, R.5
Goldman, H.6
-
6
-
-
7144256236
-
Morphology of sporadic colorectal cancer with DNA replication errors
-
Jass JR, Do KA, Simms LA, Iino H, Wynter C, Pillay SP, et al. Morphology of sporadic colorectal cancer with DNA replication errors. Gut 1998;42:673-9.
-
(1998)
Gut
, vol.42
, pp. 673-679
-
-
Jass, J.R.1
Do, K.A.2
Simms, L.A.3
Iino, H.4
Wynter, C.5
Pillay, S.P.6
-
7
-
-
14544300998
-
Systematic review of microsatellite instability and colorectal cancer prognosis
-
Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23: 609-18.
-
(2005)
J Clin Oncol
, vol.23
, pp. 609-618
-
-
Popat, S.1
Hubner, R.2
Houlston, R.S.3
-
8
-
-
58749102767
-
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
-
Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009;100:266-73.
-
(2009)
Br J Cancer
, vol.100
, pp. 266-273
-
-
Koopman, M.1
Kortman, G.A.2
Mekenkamp, L.3
Ligtenberg, M.J.4
Hoogerbrugge, N.5
Antonini, N.F.6
-
9
-
-
84881255039
-
Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy {+/-} cetuximab
-
Smith CG, Fisher D, Claes B, Maughan TS, Idziaszczyk S, Peuteman G, et al.Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy {+/-} cetuximab. Clin Cancer Res 2013;19:4104-13.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 4104-4113
-
-
Smith, C.G.1
Fisher, D.2
Claes, B.3
Maughan, T.S.4
Idziaszczyk, S.5
Peuteman, G.6
-
10
-
-
34447121322
-
Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer
-
Malesci A, Laghi L, Bianchi P, Delconte G, Randolph A, Torri V, et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res 2007;13:3831-9.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 3831-3839
-
-
Malesci, A.1
Laghi, L.2
Bianchi, P.3
Delconte, G.4
Randolph, A.5
Torri, V.6
-
11
-
-
19944365184
-
Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases
-
Buckowitz A, Knaebel HP, Benner A, Blaker H, Gebert J, Kienle P, et al. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer 2005;92:1746-53.
-
(2005)
Br J Cancer
, vol.92
, pp. 1746-1753
-
-
Buckowitz, A.1
Knaebel, H.P.2
Benner, A.3
Blaker, H.4
Gebert, J.5
Kienle, P.6
-
12
-
-
0141593677
-
BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair
-
Wang L, Cunningham JM, Winters JL, Guenther JC, French AJ, Boardman LA, et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003; 63:5209-12.
-
(2003)
Cancer Res
, vol.63
, pp. 5209-5212
-
-
Wang, L.1
Cunningham, J.M.2
Winters, J.L.3
Guenther, J.C.4
French, A.J.5
Boardman, L.A.6
-
13
-
-
20544437157
-
BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes
-
Domingo E, Niessen RC, Oliveira C, Alhopuro P, Moutinho C, Espin E, et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 2005;24:3995-8.
-
(2005)
Oncogene
, vol.24
, pp. 3995-3998
-
-
Domingo, E.1
Niessen, R.C.2
Oliveira, C.3
Alhopuro, P.4
Moutinho, C.5
Espin, E.6
-
14
-
-
0037194728
-
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status
-
Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934.
-
(2002)
Nature
, vol.418
, pp. 934
-
-
Rajagopalan, H.1
Bardelli, A.2
Lengauer, C.3
Kinzler, K.W.4
Vogelstein, B.5
Velculescu, V.E.6
-
15
-
-
22244472992
-
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers
-
Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:6063-9.
-
(2005)
Cancer Res
, vol.65
, pp. 6063-6069
-
-
Samowitz, W.S.1
Sweeney, C.2
Herrick, J.3
Albertsen, H.4
Levin, T.R.5
Murtaugh, M.A.6
-
16
-
-
75749102647
-
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial
-
Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28:466-74.
-
(2010)
J Clin Oncol
, vol.28
, pp. 466-474
-
-
Roth, A.D.1
Tejpar, S.2
Delorenzi, M.3
Yan, P.4
Fiocca, R.5
Klingbiel, D.6
-
17
-
-
34447277453
-
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial
-
Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007;370: 135-42.
-
(2007)
Lancet
, vol.370
, pp. 135-142
-
-
Koopman, M.1
Antonini, N.F.2
Douma, J.3
Wals, J.4
Honkoop, A.H.5
Erdkamp, F.L.6
-
18
-
-
59749091477
-
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
-
Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-72.
-
(2009)
N Engl J Med
, vol.360
, pp. 563-572
-
-
Tol, J.1
Koopman, M.2
Cats, A.3
Rodenburg, C.J.4
Creemers, G.J.5
Schrama, J.G.6
-
19
-
-
79959337678
-
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial
-
Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377: 2103-14.
-
(2011)
Lancet
, vol.377
, pp. 2103-2114
-
-
Maughan, T.S.1
Adams, R.A.2
Smith, C.G.3
Meade, A.M.4
Seymour, M.T.5
Wilson, R.H.6
-
20
-
-
79959571031
-
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial
-
Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2011;12:642-53.
-
(2011)
Lancet Oncol
, vol.12
, pp. 642-653
-
-
Adams, R.A.1
Meade, A.M.2
Seymour, M.T.3
Wilson, R.H.4
Madi, A.5
Fisher, D.6
-
21
-
-
34447255724
-
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial
-
Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370:143-52.
-
(2007)
Lancet
, vol.370
, pp. 143-152
-
-
Seymour, M.T.1
Maughan, T.S.2
Ledermann, J.A.3
Topham, C.4
James, R.5
Gwyther, S.J.6
-
22
-
-
84859583692
-
KRAS and BRAF mutation analysis in routine molecular diagnostics: Comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA
-
Heideman DA, Lurkin I, Doeleman M, Smit EF, Verheul HM, Meijer GA, et al. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. J Mol Diagn 2012;14:247-55.
-
(2012)
J Mol Diagn
, vol.14
, pp. 247-255
-
-
Heideman, D.A.1
Lurkin, I.2
Doeleman, M.3
Smit, E.F.4
Verheul, H.M.5
Meijer, G.A.6
-
23
-
-
77954215850
-
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab
-
Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Borger ME, et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010;46:1997-2009.
-
(2010)
Eur J Cancer
, vol.46
, pp. 1997-2009
-
-
Tol, J.1
Dijkstra, J.R.2
Klomp, M.3
Teerenstra, S.4
Dommerholt, M.5
Vink-Borger, M.E.6
-
24
-
-
73349114941
-
KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: Results from the MRC FOCUS trial
-
Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009;27:5931-7.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5931-5937
-
-
Richman, S.D.1
Seymour, M.T.2
Chambers, P.3
Elliott, F.4
Daly, C.L.5
Meade, A.M.6
-
25
-
-
0032534069
-
A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer
-
Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57.
-
(1998)
Cancer Res
, vol.58
, pp. 5248-5257
-
-
Boland, C.R.1
Thibodeau, S.N.2
Hamilton, S.R.3
Sidransky, D.4
Eshleman, J.R.5
Burt, R.W.6
-
26
-
-
79954605264
-
Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors results from the Colon Cancer Family Registry
-
Cicek MS, Lindor NM, Gallinger S, Bapat B, Hopper JL, Jenkins MA, et al. Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors results from the Colon Cancer Family Registry. J Mol Diagn 2011;13:271-81.
-
(2011)
J Mol Diagn
, vol.13
, pp. 271-281
-
-
Cicek, M.S.1
Lindor, N.M.2
Gallinger, S.3
Bapat, B.4
Hopper, J.L.5
Jenkins, M.A.6
-
27
-
-
0037083484
-
Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors
-
Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002; 20:1043-8.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1043-1048
-
-
Lindor, N.M.1
Burgart, L.J.2
Leontovich, O.3
Goldberg, R.M.4
Cunningham, J.M.5
Sargent, D.J.6
-
28
-
-
84869766270
-
Molecular platforms utilized to detect BRAF V600E mutation in melanoma
-
Curry JL, Torres-Cabala CA, Tetzlaff MT, Bowman C, Prieto VG. Molecular platforms utilized to detect BRAF V600E mutation in melanoma. Semin Cutan Med Surg 2012;31:267-73.
-
(2012)
Semin Cutan Med Surg
, vol.31
, pp. 267-273
-
-
Curry, J.L.1
Torres-Cabala, C.A.2
Tetzlaff, M.T.3
Bowman, C.4
Prieto, V.G.5
-
29
-
-
0141815907
-
Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability
-
Ishikawa T, Fujita T, Suzuki Y, Okabe S, Yuasa Y, Iwai T, et al. Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Res 2003;63: 5564-72.
-
(2003)
Cancer Res
, vol.63
, pp. 5564-5572
-
-
Ishikawa, T.1
Fujita, T.2
Suzuki, Y.3
Okabe, S.4
Yuasa, Y.5
Iwai, T.6
-
30
-
-
22244434945
-
Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers
-
Kloor M, Becker C, Benner A, Woerner SM, Gebert J, Ferrone S, et al. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res 2005;65:6418-24.
-
(2005)
Cancer Res
, vol.65
, pp. 6418-6424
-
-
Kloor, M.1
Becker, C.2
Benner, A.3
Woerner, S.M.4
Gebert, J.5
Ferrone, S.6
-
31
-
-
0037445248
-
Role of DNA mismatch repair defects in the pathogenesis of human cancer
-
Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 2003;21:1174-9.
-
(2003)
J Clin Oncol
, vol.21
, pp. 1174-1179
-
-
Peltomaki, P.1
-
32
-
-
77953292460
-
BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome
-
Saridaki Z, Papadatos-Pastos D, Tzardi M, Mavroudis D, Bairaktari E, Arvanity H, et al. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. Br J Cancer 2010;102:1762-8.
-
(2010)
Br J Cancer
, vol.102
, pp. 1762-1768
-
-
Saridaki, Z.1
Papadatos-Pastos, D.2
Tzardi, M.3
Mavroudis, D.4
Bairaktari, E.5
Arvanity, H.6
-
33
-
-
79952463028
-
Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAF(V600E) mutation
-
Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 2011;128:2075-84.
-
(2011)
Int J Cancer
, vol.128
, pp. 2075-2084
-
-
Tie, J.1
Gibbs, P.2
Lipton, L.3
Christie, M.4
Jorissen, R.N.5
Burgess, A.W.6
-
34
-
-
3242686837
-
BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum
-
Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV, Walsh MD, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004;53:1137-44.
-
(2004)
Gut
, vol.53
, pp. 1137-1144
-
-
Kambara, T.1
Simms, L.A.2
Whitehall, V.L.3
Spring, K.J.4
Wynter, C.V.5
Walsh, M.D.6
-
35
-
-
84881640407
-
Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication
-
Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 2013;105:1151-6.
-
(2013)
J Natl Cancer Inst
, vol.105
, pp. 1151-1156
-
-
Lochhead, P.1
Kuchiba, A.2
Imamura, Y.3
Liao, X.4
Yamauchi, M.5
Nishihara, R.6
-
36
-
-
78649473910
-
The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
-
Farina-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, Rutten HJ, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010;21:2396-403.
-
(2010)
Ann Oncol
, vol.21
, pp. 2396-2403
-
-
Farina-Sarasqueta, A.1
Van Lijnschoten, G.2
Moerland, E.3
Creemers, G.J.4
Lemmens, V.E.5
Rutten, H.J.6
-
37
-
-
84856512550
-
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: Results from intergroup trial CALGB 89803
-
Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 2012;18:890-900.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 890-900
-
-
Ogino, S.1
Shima, K.2
Meyerhardt, J.A.3
McCleary, N.J.4
Ng, K.5
Hollis, D.6
-
38
-
-
79960149283
-
Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer
-
Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, et al. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol 2011;29:2675-82.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2675-2682
-
-
Price, T.J.1
Hardingham, J.E.2
Lee, C.K.3
Weickhardt, A.4
Townsend, A.R.5
Wrin, J.W.6
-
39
-
-
33846201272
-
New insight into BRAF mutations in cancer
-
Dhomen N, Marais R. New insight into BRAF mutations in cancer. Curr Opin Genet Dev 2007;17:31-9.
-
(2007)
Curr Opin Genet Dev
, vol.17
, pp. 31-39
-
-
Dhomen, N.1
Marais, R.2
-
40
-
-
79958817037
-
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
-
Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011;117:4623-32.
-
(2011)
Cancer
, vol.117
, pp. 4623-4632
-
-
Tran, B.1
Kopetz, S.2
Tie, J.3
Gibbs, P.4
Jiang, Z.Q.5
Lieu, C.H.6
-
41
-
-
62549089251
-
Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatinand/or irinotecan-based chemotherapy
-
Catalano V, Loupakis F, Graziano F, Torresi U, Bisonni R, Mari D, et al. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatinand/or irinotecan-based chemotherapy. Br J Cancer 2009;100:881-7.
-
(2009)
Br J Cancer
, vol.100
, pp. 881-887
-
-
Catalano, V.1
Loupakis, F.2
Graziano, F.3
Torresi, U.4
Bisonni, R.5
Mari, D.6
-
42
-
-
84856004661
-
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of north central cancer treatment group phase III trials N9741 and N9841
-
Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 2012;30:263-7.
-
(2012)
J Clin Oncol
, vol.30
, pp. 263-267
-
-
Franko, J.1
Shi, Q.2
Goldman, C.D.3
Pockaj, B.A.4
Nelson, G.D.5
Goldberg, R.M.6
|